Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Abstract Text:

Eric C LaCasse,Gabriele G Cherton-Horvat,Kimberley E Hewitt,Lori J Jerome,Stephen J Morris,Ekambar R Kandimalla,Dong Yu,Hui Wang,Wei Wang,Ruiwen Zhang,Sudhir Agrawal,John W Gillard,Jon P Durkin,

PURPOSE: Cancer cells can use X-linked inhibitor of apoptosis (XIAP) to evade apoptotic cues, including chemotherapy. The antitumor potential of AEG35156, a novel second-generation antisense oligonucleotide directed toward XIAP, was assessed in human cancer models when given as a single agent and in combination with clinically relevant chemotherapeutics. EXPERIMENTAL DESIGN: AEG35156 was characterized for its ability to cause dose-dependent reductions of XIAP mRNA and protein in vitro and in vivo, to sensitize cancer cell lines to death stimuli, and to exhibit antitumor activity in multiple human cancer xenograft models as a single agent or in combination with chemotherapy. RESULTS: AEG35156 reduced XIAP mRNA levels with an EC50 of 8 to 32 nmol/L and decreased XIAP protein levels by >80%. Loss of XIAP protein correlated with increased sensitization to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis in Panc-1 pancreatic carcinoma cells. AEG35156 exhibited potent antitumor activity relative to control oligonucleotides in three human cancer xenograft models (prostate, colon, and lung) and was capable of inducing complete tumor regression when combined with taxanes. Antitumor effects of AEG35156 correlated with suppression of tumor XIAP levels. CONCLUSIONS: AEG35156 reduces XIAP levels and sensitizes tumors to chemotherapy. AEG35156 is presently under clinical assessment in multiple phase I trials in cancer patients as a single agent and in combination with docetaxel in solid tumors or cytarabine/idarubicin in leukemia.

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Publishing Authors By Initials

EC LaCasse,GG Cherton-Horvat,KE Hewitt,LJ Jerome,SJ Morris,ER Kandimalla,D Yu,H Wang,W Wang,R Zhang,S Agrawal,JW Gillard,JP Durkin,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Clinical cancer research : an official journal of

VOLUME: 12

Page Numbers: 5231-41

Journal Abbreviation:

ISSN: 1078-0432

DAY: 1

MONTH: Sep

YEAR: 2006

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9502500

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.

AFFILIATION: Aegera Therapeutics, Inc., Montreal, Quebec, Canada.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Clin Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis Related Publications

• 2-methylbutyryl-CoA dehydrogenase deficiency in Hmong infants identified by expanded newborn screen.
• A comparison of efficacy of the key informant and community survey methods in the identification of childhood disability in Jamaica.
• A comparison of the effectiveness of computer-based learning courses among nursing staff.
• Antigen and antibody testing for the diagnosis of blastomycosis in dogs.
• Central and spinal somatosensory conduction times during hypothermic cardiopulmonary bypass and some observations on the effects of fentanyl and isoflurane anesthesia.
• Clinical data exchange models. Matching HIE goals with IT foundations.
• Determination of optical properties of superficial volumes of layered tissue phantoms.
• Educating nursing students about the dangers of drinking games.
• In vivo determination of skin near-infrared optical properties using diffuse optical spectroscopy.
• Language and Independence in Adolescents With and Without a History of Specific Language Impairment (SLI).
• Methyl hydantoin in the treatment of epilepsy.
• Oestriol excretion in pregnancy.
• PARACERVICAL BLOCK FOR LABOR.
• Parental Perspectives During the Transition to Adulthood of Adolescents With a History of Specific Language Impairment (SLI).
• Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.
• Prevalence of cerebral palsy in 8-year-old children in three areas of the United States in 2002: a multisite collaboration.
• Rupture of the rectus abdominis muscle.
• TRANSPLACENTAL FOETAL BLOOD-LOSS.
• The theory and practice of group psychotherapy.
• Topics in biomedical optics: introduction.
• Two Distinct T Cell Subsets, CD4+ and CD8+CD60+, and Their Cytokines Are Required for In Vitro Induction of Human Ragweed-Specific Memory IgE Responses.